Practical Approaches To Faster Study Start-Ups: Making Progress In The Face Of Industry Headwinds

As clinical technologies advance and become more widespread, it's surprising that trial durations are on the rise. According to research from the Tufts Center for the Study of Drug Development, the timelines for initiating studies, from protocol approval to the first patient's visit, have increased by as much as 45% between 2015 and 2021. With the urgency of getting products to market higher than ever, how can the industry reverse this concerning trend?

In an insightful discussion, the following industry leaders delve into the real-world challenges faced during the start-up phase of clinical studies, as well as the underlying causes:

• Kerry Randall, VP, Global Site Activation, IQVIA R&D Services
• Raphaelle Gilg, Strategy and Operations Manager, Novartis
• Rodrigo Guimaraes, Vice President, Global Site Activation, IQVIA R&D Solutions
• Rosemary Shirey, Assoc. Director, Client Services, IQVIA Technologies

From their provided insight, learn how teams can leverage organizational, procedural, and technological solutions to recapture valuable days, weeks, and even months in the activation timelines of research sites. In addition, the speakers also provide a collection of effective strategies for expediting the initiation of studies, even in the face of regulatory and economic challenges.

Watch the full webinar below to begin streamlining processes across multiple countries, simplify the workload for research sites, eliminate redundant tasks and waiting periods, and prioritize relationships and collaboration over excessive documentation.